- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT01565980
Mindfulness Therapy for Individuals With Lung Cancer
A Mindfulness Intervention for Symptom Management in Lung Cancer
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60208
- Northwestern University
-
-
Michigan
-
East Lansing, Michigan, Verenigde Staten, 48824
- Michigan State University
-
Jackson, Michigan, Verenigde Staten, 49201
- Allegiance Health
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Able to understand and speak English
- at least 21 years old
- active treatment for a diagnosis of non-small cell lung cancer
- Karnofsky score > 80
- have a telephone by which they can be reached
Exclusion Criteria:
- current substance abuse other than tobacco
- active treatment for psychiatric disorders excluding depression, and/or use of antipsychotic medications that would impede study participation.
- cognitive impairment
- active participation in mindfulness-based classes, guided imagery, yoga, or relaxation therapy courses
- diagnosis of small cell lung cancer
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Ondersteunende zorg
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Enkel
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
---|---|
Actieve vergelijker: symptom assessment
6 weeks of symptom assessment phone calls.
|
attention control receives a weekly symptom assessment phone interview for 6 weeks.
|
Experimenteel: Mindfulness intervention
Participants receive 6 weeks of the home-based mindfulness intervention, and weekly symptom assessment phone calls.
|
attention control receives a weekly symptom assessment phone interview for 6 weeks.
Participants will receive a weekly home-based mindfulness intervention, and symptom assessment phone interviews for 6 weeks.
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
M.D. Anderson Symptom Inventory (MDASI)
Tijdsspanne: Time 2 (week 8), Time 3 (week 11), and overall average for group comparisons.
|
Symptom Severity and interference were measured with the M.D. Anderson Symptom Inventory (MDASI) .
The MDASI is a multisymptom patient-reported outcome measure.
The MDASI has 13 core items include symptoms found to have the highest frequency and/or severity in patients with various cancers and treatment types (pain, fatigue, nausea, vomiting, disturbed sleep, distress, shortness of breath, memory difficulties, lack of appetite, drowsiness, dry mouth, sadness,numbness and tingling.
Patients rate the severity of each symptom "at its worst" using 0-10 numerical rating scales with 0 = "not present" and 10 = "as bad as you can imagine."
The measure includes 5 symptom interference items which ask how much all symptoms, interfere with domains (walking, work, general activity, mood, relations with others, enjoyment of life) also rated on a 0-10 scale (0 = "did not interfere"; 10 = "interfered completely").
The 13 severity (range 0 - 130) and 5 interference items (range 0 - 50) are summed.
|
Time 2 (week 8), Time 3 (week 11), and overall average for group comparisons.
|
SF-36
Tijdsspanne: Time 2 (week 8), Time 3 (week 11), and overall average for group comparisons.
|
Health-related Quality of Life (HRQOL) Indices (Physical/Emotional Function, Role Function, Pain, General Health, Vitality, Mental/Physical Health)HRQOL(SF-36) calculated using Quality Metric, Inc. an algorithm producing normal scores (1-100 range).
With normed scoring, general population has mean=50, SD=10.
For the minimum and maximum values in each of the scale ranges provided, higher values represent a better outcome.
|
Time 2 (week 8), Time 3 (week 11), and overall average for group comparisons.
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
---|---|---|
Center for Epidemiologic Studies Depression (CES-D)
Tijdsspanne: Time 2 (week 8), Time 3 (week 11), and overall average for group comparisons.
|
The score is the sum of the 20 questions.
Each item has a range of 1 - 4 for frequency of a behavior or mental state in the past week ; 1 - Rarely or none of the time (less than 1 day); 2 = Some or a little of the time (1-2 days); 3 = Occasionally or a moderate amount of time (3-4 days); 4 = Most or all of the time (5-7 days).
Possible range is 0-60.
There are 4 reverse-scored items (questions 4, 8, 12, and 16).
A score of 16 points or more is considered depressed.
|
Time 2 (week 8), Time 3 (week 11), and overall average for group comparisons.
|
Cancer Dyspnea Scale
Tijdsspanne: Time 2 (week 8), Time 3 (week 11), and overall average for group comparisons.
|
The cancer dyspnea scale (CDS) has 12 Likert scale items ( 1 = Not at all, 5 = Very much) that ask questions about breathlessness or difficulty in breathing during the past few days. The CDS has an overall score (range 0-42) and 3 subscales that measure the amount of effort with breathing, anxiety associated with breathing, and discomfort associated with breathing. The 3 subscales are calculated by: 1) effort (items 4+6+8+10+12) - 5 [range 0 (no dyspnea effort)-20 (worst dyspnea effort)]; 2) anxiety (items 5+7+9+11) - 4 [range 0 (no dyspnea anxiety) - 16 (worst dyspnea anxiety)]; 3) discomfort [15 - (items 1+2+3) {range 0 (no dyspnea discomfort) - 12 (worst dyspnea discomfort)}]. The total dyspnea score is derived by adding the total subscale scores. The subscale score subtractions are to make adjustments for 0 as a state of absence of dyspnea (thus total dyspnea summary scores range from 0 to 42). |
Time 2 (week 8), Time 3 (week 11), and overall average for group comparisons.
|
Worry (Cancer-related and General)
Tijdsspanne: Time 2 (week 8), Time 3 (week 11), and overall average for group comparisons.
|
Both cancer-related and general worry were measured with 3 item scales.
Cancer-related worry had three statements asking about level of worry related to diagnosis, treatment, and worry interference using a 1 = "not at all" to 5 = "most or all the time" scale, range 3-15.
Items are summed.
General worry used an abbreviated brief Penn State Worry questionnaire with 3 statements that measure how typical that statements are in describing the person.
Uses a 3 item scale with 1 = "not at all typical" to 5 = "very typical".
the range is 3-15.
Items are summed.
|
Time 2 (week 8), Time 3 (week 11), and overall average for group comparisons.
|
Pittsburgh Sleep Symptom Questionnaire-Insomnia (PSSQ_I)
Tijdsspanne: Time 2 (week 8), Time 3 (week 11), and overall average for group comparisons.
|
The PSSQ_I has 13 self rated questions.
The first 5 items, used to determine sleep quality (presence; frequency of insomnia problems) are rated [0 = never to 5 = always, 5-7 days per week; (range 0-25)] and items 6 to 13 are aimed at identifying the degree of interference experienced from sleep impairment (rated 0=not at all to 4=extremely on Likert scale; range 0 - 32).
|
Time 2 (week 8), Time 3 (week 11), and overall average for group comparisons.
|
Baseline Values for All Measures.
Tijdsspanne: Baseline.
|
Description of all measures are described elsewhere.
Provided are the means and standard deviations for baseline comparisons.
|
Baseline.
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Rebecca Lehto, PhD, Michigan State University
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start
Primaire voltooiing (Werkelijk)
Studie voltooiing (Werkelijk)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Schatting)
Updates van studierecords
Laatste update geplaatst (Schatting)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- CTSI grant
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .
Klinische onderzoeken op Longkanker
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)VoltooidAdenocarcinoom van de dunne darm | Stadium III Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIA Adenocarcinoom van de dunne darm AJCC v8 | Stadium IIIB dunne darm adenocarcinoom AJCC v8 | Stadium IV Adenocarcinoom van de dunne darm AJCC v8 | Ampulla van Vater Adenocarcinoom | Stadium III... en andere voorwaardenVerenigde Staten
-
University of UtahNational Cancer Institute (NCI)WervingVermoeidheid | Sedentaire levensstijl | Gemetastaseerd prostaatcarcinoom | Stadium IV prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVA prostaatkanker AJCC (American Joint Committee on Cancer) v8 | Stadium IVB prostaatkanker AJCC (American Joint Committee on Cancer) v8Verenigde Staten
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...VoltooidBestudeer Chinese vrouwen die zich niet hebben gehouden aan de richtlijnen voor screening op mammografie van de American Cancer SocietyVerenigde Staten
-
BioNTech SESeventh Framework ProgrammeVoltooidBorstkanker (Triple Negative Breast Cancer (TNBC))Zweden, Duitsland
-
Novartis PharmaceuticalsVoltooidGeavanceerde Triple Negative Breast Cancer (TNBC) met hoge TAM'sFrankrijk, Italië, Oostenrijk, Taiwan, Verenigde Staten, Spanje, Australië, Korea, republiek van, België, Duitsland, Hongkong, Kalkoen
-
Rashmi Verma, MDNational Cancer Institute (NCI)WervingCastratieresistent prostaatcarcinoom | Gemetastaseerd prostaatadenocarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNog niet aan het wervenProstaatcarcinoom | Stadium IVB Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)WervingAnatomische fase II borstkanker AJCC v8 | Anatomische fase III borstkanker AJCC v8 | Borstcarcinoom in een vroeg stadium | Anatomische fase I Borstkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
Jonsson Comprehensive Cancer CenterIngetrokkenProstaat Adenocarcinoom | Prostaatkanker stadium II AJCC v8 | Stadium IIC prostaatkanker AJCC v8 | Stadium IIA prostaatkanker AJCC v8 | Stadium IIB prostaatkanker AJCC v8 | Fase I Prostaatkanker American Joint Committee on Cancer (AJCC) v8Verenigde Staten
-
University of Southern CaliforniaNational Cancer Institute (NCI)WervingLokaal gevorderd pancreasadenocarcinoom | Inoperabel pancreasadenocarcinoom | Fase III Pancreaskanker American Joint Committee on Cancer v8Verenigde Staten
Klinische onderzoeken op symptom assessment
-
Vanderbilt University Medical CenterNational Institute of Mental Health (NIMH)WervingAutisme Spectrum StoornisVerenigde Staten
-
Vanderbilt University Medical CenterNational Institute of Mental Health (NIMH)WervingAutisme Spectrum StoornisVerenigde Staten
-
Baylor Research InstituteIngetrokkenGewichtsverlies | Kandidaat Bariatrische Chirurgie | Maaglediging | Sleeve gastrectomie | Diabetische gastropareseVerenigde Staten
-
IRCCS Policlinico S. MatteoVoltooidComputer Vision-syndroom | Video Display Terminal-werknemers
-
Al-Azhar UniversityWervingCariës | Uitbarsting | Body Mass IndexEgypte
-
Centre hospitalier de l'Université de Montréal...University Health Network, Toronto; University of British Columbia; McGill University en andere medewerkersWervingUrologische ziektenCanada, Verenigde Staten
-
New York UniversityVisiting Nurse Service of New YorkIngetrokken
-
VA Office of Research and DevelopmentVoltooidProstaatkankerVerenigde Staten
-
Duke UniversityActief, niet wervendColorectale kankerVerenigde Staten
-
Mutah UniversityVoltooidOveractieve blaasJordanië